Notice to Atara Biotherapeutics Shareholders Regarding Class Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ATRA?
Source: Globenewswire
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel, significantly impacting Atara's business and financial condition.
- Regulatory Risks: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials and potentially diminishing investor confidence in the company's future prospects, which could adversely affect stock performance.
- Shareholder Action Steps: Shareholders must register for this class action by May 22, 2026, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.830
Low
18.00
Averages
21.50
High
25.00
Current: 4.830
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, potentially impacting the company's financial condition significantly.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation and support during litigation.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action lawsuit against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motions set for May 22, 2026, indicating significant legal risks that could undermine shareholder confidence.
- FDA Regulatory Risks: Atara faces heightened uncertainty regarding the FDA's approval of the tabelecleucel Biologics License Application (BLA) due to manufacturing issues and deficiencies in the ALLELE study, which may jeopardize ongoing clinical trials and have a substantial negative impact on the company's business and financial condition.
- Stock Price Volatility: Following the receipt of a Complete Response Letter (CRL) on January 16, 2025, Atara's stock plummeted from $13.16 to $7.83, a decline of 40.5%, reflecting market pessimism regarding the company's regulatory prospects.
- Clinical Trial Setbacks: On January 12, 2026, Atara received another CRL indicating that its EBVALLO BLA application could not be approved, leading to a further 57% drop in stock price to $5.88, highlighting significant flaws in trial design and execution that may further erode investor confidence.
See More
Notice to Atara Biotherapeutics Shareholders Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel, significantly impacting Atara's business and financial condition.
- Regulatory Risks: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials and potentially diminishing investor confidence in the company's future prospects, which could adversely affect stock performance.
- Shareholder Action Steps: Shareholders must register for this class action by May 22, 2026, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Allegation: The complaint alleges that Atara faced manufacturing issues in its ALLELE study, making FDA approval of its BLA for tabelecleucel unlikely, while the company overstated the drug's prospects, leading to investor losses when the truth emerged.
- Increased Regulatory Risk: Atara's manufacturing problems have resulted in a heightened risk of regulatory action, rendering its public statements during the class period false and materially misleading, which exacerbated investor losses as the market learned the truth.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected investors to seek compensation through the class action, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investors' rights.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Atara Biotherapeutics for potential claims from investors who purchased securities between May 20, 2024, and January 9, 2026, highlighting the firm's commitment to investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing multiple contact options to facilitate inquiries, aiming to help them understand their legal rights and possible remedies.
- Class Action Deadline Reminder: Faruqi & Faruqi reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action against Atara, making this date critical for potential legal actions.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation underscores the importance of legal institutions in protecting investor rights, which may impact Atara's market reputation and stock performance.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the regulatory prospects of its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to choose legal counsel carefully, as Rosen Law Firm emphasizes selecting attorneys with a proven track record in securities class actions to avoid partnering with firms that merely act as intermediaries, ensuring effective protection of their rights.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, potentially impacting the company's financial condition significantly.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in securities class actions to ensure optimal representation and support during litigation.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action lawsuit against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motions set for May 22, 2026, indicating significant legal risks that could undermine shareholder confidence.
- FDA Regulatory Risks: Atara faces heightened uncertainty regarding the FDA's approval of the tabelecleucel Biologics License Application (BLA) due to manufacturing issues and deficiencies in the ALLELE study, which may jeopardize ongoing clinical trials and have a substantial negative impact on the company's business and financial condition.
- Stock Price Volatility: Following the receipt of a Complete Response Letter (CRL) on January 16, 2025, Atara's stock plummeted from $13.16 to $7.83, a decline of 40.5%, reflecting market pessimism regarding the company's regulatory prospects.
- Clinical Trial Setbacks: On January 12, 2026, Atara received another CRL indicating that its EBVALLO BLA application could not be approved, leading to a further 57% drop in stock price to $5.88, highlighting significant flaws in trial design and execution that may further erode investor confidence.
See More
Notice to Atara Biotherapeutics Shareholders Regarding Class Action
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased Atara Biotherapeutics (NASDAQ: ATRA) shares between May 20, 2024, and January 9, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery participation.
- Allegations: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the likelihood of FDA approval for tabelecleucel, significantly impacting Atara's business and financial condition.
- Regulatory Risks: The manufacturing issues have subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials and potentially diminishing investor confidence in the company's future prospects, which could adversely affect stock performance.
- Shareholder Action Steps: Shareholders must register for this class action by May 22, 2026, and upon registration, they will receive status updates throughout the case lifecycle, ensuring their rights are protected.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements Allegation: The complaint alleges that Atara faced manufacturing issues in its ALLELE study, making FDA approval of its BLA for tabelecleucel unlikely, while the company overstated the drug's prospects, leading to investor losses when the truth emerged.
- Increased Regulatory Risk: Atara's manufacturing problems have resulted in a heightened risk of regulatory action, rendering its public statements during the class period false and materially misleading, which exacerbated investor losses as the market learned the truth.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected investors to seek compensation through the class action, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investors' rights.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Atara Biotherapeutics for potential claims from investors who purchased securities between May 20, 2024, and January 9, 2026, highlighting the firm's commitment to investor rights.
- Investor Contact Information: The firm encourages affected investors to reach out directly to partner Josh Wilson, providing multiple contact options to facilitate inquiries, aiming to help them understand their legal rights and possible remedies.
- Class Action Deadline Reminder: Faruqi & Faruqi reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action against Atara, making this date critical for potential legal actions.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation underscores the importance of legal institutions in protecting investor rights, which may impact Atara's market reputation and stock performance.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in clinical trials, which overstated the regulatory prospects of its tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to choose legal counsel carefully, as Rosen Law Firm emphasizes selecting attorneys with a proven track record in securities class actions to avoid partnering with firms that merely act as intermediaries, ensuring effective protection of their rights.
See More
